Getting Comfortable — Quick Context

• Tell us the brief deal snapshot: target name, announced transaction type (buy-side/sell-side), and where you are in the process?
• Which of these best describes your role on this transaction? Options: PE deal lead / principal, Corporate development / VP M&A, Investment committee member, Deal team analyst / associate, Other (please specify)
• What's the immediate pressure point driving urgency on timing—exclusivity, auction round, board deadline, or something else? Options: Signed LOI / exclusivity window, Auction bid deadline, Internal IC/board date, Regulatory timeline, Sell-side launch/preparation, Other
• How are you feeling about the timeline right now—confident, concerned, stretched, or overwhelmed? Options: Confident, Mildly concerned, Stretched but manageable, Overwhelmed
• What would you most want a QoE report to give you in 48–72 hours that would immediately change your posture at the negotiating table?

What’s the Real Countdown?

• If the exclusivity window closed today, how differently would you act on the deal? Options: We would sign as-is, We would renegotiate price/terms, We would walk away, Unsure
• What is the exact exclusivity deadline and any internal milestones you must hit before that date?
• Who controls the decision to extend exclusivity and under what circumstances would you expect an extension to be granted? Options: Seller will not extend, Seller may extend with fee/consideration, Negotiable depending on findings, We don't know / TBD
• Which deadlines are non-negotiable for your IC or board (meeting dates, paper deadlines, approval gates)?
• How would late or incomplete diligence materially change your negotiation strategy (e.g., aggressive PA changes, walk, add reps/escrow)? Options: Push for price reduction, Insist on reps and warranties, Increase escrow/holdback, Withdraw, Other

Who Must Be Convinced Before Clocks Run Out?

• Which specific people or committees must sign off on the final recommendation and what do they fear most?
• Which stakeholders care most about valuation sensitivity versus operational risks (e.g., fund principal, CFO, integration lead)? Options: Valuation sensitivity, Operational risks, Both equally, Unsure
• How do past committee reactions to diligence findings shape the thresholds you need to meet now (tight tolerance vs. wide tolerance)? Options: Tight tolerance — small issues derail deals, Moderate tolerance — fixable issues OK, Wide tolerance — willing to absorb surprises, Unsure
• What format and level of detail does the IC expect for rapid consumption (one-pager, model attachment, red-flag summary, full report)? Options: One-pager + model, Red-flag summary only, Draft report + presentation, Full report only, Other
• When the IC hears about a single large customer risk or a disputed add-back, what’s the likely behavioral response—ask for a price cut, ask for reps, or pause the deal? Options: Price cut, Reps & warranties, Pause / request more info, Walk away, Depends on size

Where Do You Suspect the Earnings Story Will Break?

• If you had to bet $100 on the single area most likely to reduce reported EBITDA, where would you place it? Options: Add-backs that won’t hold up, Understated costs / integration needs, Revenue recognition anomalies, Working capital surprises, Other
• Tell us about any add-backs the target has presented that make you uneasy—what are they and why do they feel soft?
• Have you encountered recurring or historical adjustments in the target's financials (periodic one-offs, stock-based comp treatment, owner perks)? Options: Yes — several recurring items, A few one-offs, No obvious recurring adjustments, Don't know yet
• How critical is EBITDA at close vs. run-rate normalization for your valuation — are you focused on LTM, adjusted LTM, or normalized forward earnings? Options: LTM, Adjusted LTM, Normalized forward, We model multiple
• Would you want us to prioritize a rapid red-flag memo on add-backs even if the full QoE report is later? Options: Yes — red-flag first, No — full report only, Prefer a short interim summary, Unsure

Are Customers a Strength or a Ticking Clock?

• If a single customer represented a meaningful share of revenue, how would that change your willingness to pay full price? Options: Significantly reduce price, Require contractual protections, Accept with contingency, Wouldn't change much
• Do you have specific concentration thresholds that trigger additional concern (e.g., >20% revenue from one customer)? Options: >10%, >20%, >30%, No set threshold, Other
• Describe any known customer risks: recent attrition, pricing pressure, single-contract dependency, or undisclosed rebates/credits?
• How important is customer-level testing (sampled contract review, invoice-to-cash trace, churn analysis) to your confidence? Options: Essential, Very important, Nice to have, Not necessary
• Would you prefer quick concentration metrics first (top 10 customers, % revenue) followed by deeper testing only if red flags appear? Options: Yes — phased approach, No — full testing up front, Depends on initial findings, Other

Data Room: Is It Ready or a Roadblock?

• How would you rate the current data-room quality and accessibility—organized and complete, usable with gaps, or disorganized and missing key files? Options: Organized and complete, Usable with gaps, Disorganized / missing key files, No access yet
• Which file types or datasets are absolutely required from day one (general ledger, AR/AP ledgers, contracts, revenue sub-ledgers, capex schedules)? Options: General ledger, AR sub-ledger, AP sub-ledger, Customer contracts, Revenue sub-ledgers, Capex schedules, Other
• Are there any restrictions on data access we should know about—PII redactions, third-party confidentiality, or on-site only files? Options: PII redactions, Third-party NDAs, On-site only, No restrictions known, Other
• How quickly can additional documentation be uploaded if we request it—within hours, 24 hours, several days, or longer? Options: Within hours, 24 hours, Several days, Longer / unknown
• Would you prefer we start with a targeted data request list to unblock initial analysis, or do you want a broad, exhaustive request upfront? Options: Targeted list first, Exhaustive list upfront, Hybrid — targeted then expand, Unsure

Management: Ally, Gatekeeper, or Unknown?

• How cooperative do you expect management to be—open and transparent, defensive but reachable, or opaque and slow? Options: Open and transparent, Defensive but reachable, Opaque / slow, Unknown
• Which interviews are mission-critical (CEO, CFO, head of sales, operations lead, controller)? Options: CEO, CFO/Finance lead, Head of Sales/Commercial, Operations/COO, Controller/Accounting, Other
• What are the non-negotiable dates/times for management availability during fieldwork?
• Have you or your bankers flagged any topics management is likely to resist (e.g., customer attrition, timing of discretionary spend, related-party transactions)? Options: Other, Customer attrition, Discretionary spend timing, Related-party transactions, Revenue recognition
• If management is uncooperative, what escalation path would you want us to follow (lawyers, banker intervention, suspend work)? Options: Lawyers involvement, Banker to intercede, Pause and escalate to client, Continue with available data, Other

What Outcomes Will Let You Move Forward Confidently?

• What specific acceptance criteria would make you comfortable signing the purchase agreement (EBITDA tolerance, working capital peg, no single-customer >X%)?
• Which of the following would you treat as a deal-breaker versus a negotiable issue? Options: Material misstatement of EBITDA, Major customer loss risk, Unresolvable working capital deficit, Significant contingent liabilities, None of the above
• How do you prefer uncertainties to be handled in the SPA—price adjustment mechanics, escrows, reps/warranty caps, or walk rights? Options: Price adjustment mechanics, Escrow/holdback, Reps & warranty caps, Walk/termination rights, Combination
• What is the minimum deliverable you need from us by the exclusivity deadline to influence negotiation (e.g., red-flag memo + model, draft QoE)? Options: Red-flag memo + model, Draft QoE report, Presentation to IC, Detailed working papers only, Other
• How will you measure the success of our engagement in the 30 days after close (accuracy of adjustments, speed of support, usability of report)? Options: Accuracy of adjustments, Speed of interim support, Usability/presentation to IC, Helped avoid overpayment, Other

Escalation & Decision Rules — If We Find Trouble, What Then?

• If we surface a material issue mid-fieldwork, how do you want it communicated—immediate call, written red-flag, or only after validation? Options: Immediate call + brief note, Written red-flag only, Validate then communicate, Prefer escalation to banker/lawyer first
• What magnitude of potential EBITDA adjustment would trigger immediate IC notification (absolute $ amount or % of purchase price)? Options: $>1M, $>5M, >=5% of price, >=10% of price, Other / specify
• Who should be on the escalation distribution list if we find a fatal flaw (internal names and external advisors)?
• Would you prefer we propose mitigation language for the SPA as part of our red-flag memo (yes/no), and if yes, which levers are highest priority? Options: Yes — propose SPA language, No — factual only, Yes for price adjustments, Yes for escrow/reps, Other
• If a material issue is identified close to the exclusivity expiry, what's your preferred path: immediate renegotiation, seek extension, or walk away? Options: Renegotiate immediately, Seek extension, Walk away, Depends on issue

Practical Constraints — Logistical and Legal Boundaries

• Are there any pending legal, regulatory, or third-party approvals that could limit our scope (customer NDAs, vendor consents, data residency rules)? Options: Customer NDAs, Vendor consents, Data residency rules, No known limits, Other
• Do you expect material related-party transactions or legacy contracts that require special handling? Options: Yes — several, Possibly a few, No, Unsure
• Are we permitted to contact customers directly for confirmation testing, or must we route questions through management or the banker? Options: Direct contact allowed, Route through management, Route through banker, Not allowed
• Will any of the target's systems be inaccessible during fieldwork (ERP downtime, month-end close, or seasonal blackout)? Options: Yes — ERP downtime, Month-end close constraints, Seasonal blackout, No known downtime, Unknown
• What documentation retention or audit trail expectations should we observe for post-close defense of our findings? Options: Full working papers retained, Summary level only, Client-specified retention, No preference

How Do You Want Us to Work With Your Team?

• What level of day-to-day access do you want between our lead and your deal lead—direct collaboration, weekly syncs, or only milestone updates? Options: Direct collaboration, Daily brief check-ins, Weekly syncs, Milestone updates only
• Who should be our primary point of contact for logistics, data requests, and scheduling?
• Would you like us to prepare an initial scope-and-fee trial proposal for approval within 24–48 hours? Options: Yes — within 24 hours, Yes — within 48 hours, No — take more time, Unsure
• How do you prefer interim communication—secure email, platform messages, or scheduled calls? Options: Secure email, Platform messages, Scheduled calls, Combination
• Are there any internal review cycles we should build into our timeline (legal review of our questions, CFO clearance for interviews)? Options: Legal review required, CFO clearance required, No internal review cycles, Other

Locking the Plan — Next Steps to Protect the Exclusivity

• If we agree a 48–72 hour rapid-scope start, what are the top three must-have deliverables we should commit to by the exclusivity midpoint?
• Which of these immediate actions would you prioritize: rapid red-flag memo, preliminary working-capital peg, customer concentration snapshot, or full QoE draft? Options: Rapid red-flag memo, Prelim working-capital peg, Customer concentration snapshot, Full QoE draft, Other
• What approvals do we need from you to begin (signed engagement letter, scope sign-off, fee authorization)? Options: Signed engagement letter, Scope sign-off, Fee authorization, None / verbal OK
• Realistically, when can we get initial data-room access and management interview slots confirmed? Options: Within 24 hours, 24–48 hours, 3–5 days, Longer / TBD
• Before we start, is there anything you’re worried we might miss or underestimate that you want called out up front?

• Deal Facts Alignment — Current State & Consequence
• QoE & Add-Backs Diagnostic Walkthrough
• Working Capital Normalization & Cash Impact Workshop
• Revenue Concentration & Customer Risk Simulation
• Investment-Committee Ready — Decision & Negotiation Ask

• Prepare negotiation language options (escrow %, holdback period, earn-out triggers) with modeled $ outcomes.
• Agree on a defensible target working capital metric and normalization approach tied to deal facts.
• Quantify the cash and price impact under the agreed target vs reported WC.
• List specific documents and owner actions required to support the normalization before exclusivity lapses.
• Deliver a WC normalization memo with benchmarks, assumptions, and model outputs for IC use.
• Request AR/AP transactional detail and confirmation of any timing anomalies from management.
• If concentration or seasonality risk is material, schedule a deep-dive with collections and procurement owners.
• Anchor: Confirm Current State & Consequence
• Produce a mapped view from concentration facts → scenario → $ valuation impact → recommended negotiation action.
• Agree on which mitigation levers are acceptable to propose to the seller and the fallback positions.
• Identify specific customer-level documentation required to reduce uncertainty before IC presentation.
• Request customer contracts, recent sales memos, and any customer-specific margin schedules.
• Opening & Meeting Objectives
• If customer concentration risk remains material, plan an expedited reference check or customer call.
• One-Line Current State & Consequence
• Produce an IC-ready decision package with a single recommended negotiation ask and clear fallback positions.
• Achieve alignment on required evidence and commitments to obtain it before the exclusivity deadline.
• Confirm owners and dates for seller negotiation, document delivery, and final report drafting.
• Finalize the IC slide deck and one-page ask summary for circulation to the investment committee.
• Book the seller negotiation meeting and prepare the negotiation script tied to the accepted valuation scenarios.
• Track outstanding evidence items with owners and escalate any missing critical documents immediately.
• Produce one agreed one-sentence current state that will be referenced in all analysis.
• Quantify the top-line consequence(s) (estimated $ delta, range, and materiality to purchase price).
• List and assign owners for all critical data gaps with required delivery dates tied to the exclusivity timeline.
• Finalize and circulate the one-sentence current state to all attendees within 24 hours.
• Owner to upload missing data-room items (AR aging, customer contracts, add-back backup) by the committed date.
• Schedule the QoE Diagnostic Walkthrough once key data items are available.
• Recap: Agreed Current State & Consequence
• Agree on a definitive list of QoE adjustments categorized by status (accepted / needs evidence / rejected).
• Quantify the EBITDA delta and resulting valuation range attributable to accepted adjustments.
• Identify outstanding evidence required to convert 'needs evidence' items to 'accepted' before negotiation deadlines.
• Produce a QoE adjustment schedule with $ impact and required supporting docs for each 'needs evidence' item.
• Request and track delivery of primary evidence (invoices, contracts, payroll records) from assigned owners.
• Update the valuation model with accepted adjustments and circulate a sensitivity table for IC use.
• One-Sentence Future State Preview
• Concentration Analysis Presentation
• Review Historical WC Drivers
• QoE Methodology & Acceptance Criteria
• One-Sentence Current State Draft
• Executive Summary of Findings
• Loss Scenarios & Valuation Impact
• Consequence Quantification
• Normalization Methodology & Target WC
• Live P&L Walk-through (sample items)
• Recommended Negotiation Position
• Negotiation & Mitigation Options
• Confidence Levels & Evidence Gaps
• Valuation Sensitivity — EBITDA to Price
• Live Model: Cash & Purchase Price Adjustment Impact
• Critical Data & Access Gaps
• Risk Items & Escalation Triggers
• Validation & Forced Decisions
• Validation & Required Evidence
• Decision, Timing & Next Steps
• Agreement & Next Steps

• Prepare Quality of Earnings (QoE) Report
• Normalize EBITDA and Substantiate Add‑backs
• Build Working Capital Normalization Schedule
• Perform Revenue Cutoff and Recognition Testing
• Analyze Customer Concentration and Churn Risk
• Reconcile General Ledger to Financial Statements
• Analyze Accounts Receivable Aging and Bad Debt Reserve
• Inventory Valuation and Obsolescence Testing
• Extract Debt‑like Items and Cash Flow Adjustments
• Quantify Post‑close Integration Costs and Synergies
• Perform Tax Provision and Contingent Liability Review
• Deliver Executive Findings Deck for Investment Committee
• Produce Vendor Due Diligence (VDD) Report

Prepare Quality of Earnings (QoE) Report

• Do you require a formal QoE report for this deal? Options: Yes, No, Unsure
• Which reporting periods should the QoE cover? Options: Most recent fiscal year, Last 12 months (LTM), 3-year trend, Custom (please specify)
• Are audited financial statements available for the periods in scope? Options: Audited, Unaudited, Both, Not available
• Do you want adjustments categorized by type (non‑recurring, owner compensation, related party, accounting policy differences)? Options: Yes, No
• What is the primary decision use of the QoE (price adjustment, covenant setting, negotiation support, vendor diligence)? Options: Purchase price negotiation, Investment committee briefing, Vendor diligence / sell‑side, Covenant/financing support, Other
• Are there specific financial statement line items or departments you believe require focused review (e.g., revenue streams, SG&A, cost of goods sold)?

Normalize EBITDA and Substantiate Add‑backs

• Do you expect management to propose add‑backs to EBITDA that require validation? Options: Yes, No, Unknown
• Please select the types of add‑backs you want substantiated (select all that apply). Options: Owner/related party compensation, One‑time legal or settlement costs, Non‑cash stock‑based compensation, Transaction‑related expenses, Other
• What materiality threshold should we apply for flagging unsubstantiated add‑backs? Options: >$250k, >$500k, >$1m, Percentage of EBITDA (please specify), No threshold — flag all
• Do you require source‑document level testing (payroll records, invoices, contracts) to substantiate add‑backs? Options: Yes — sample testing, Yes — full testing, No — management representation only
• Are there pre‑identified recurring adjustments management claims should be normalized instead of added back? Options: Yes, No, Not sure
• Is rapid turnaround required to influence the exclusivity window or next bid deadline? If yes, specify deadline.

Build Working Capital Normalization Schedule

• Do you want a standardized working capital normalization (DSO, DPO, DIO) or a custom schedule aligned to buyer accounting policy? Options: Standard (DSO/DPO/DIO), Custom policy alignment, Both
• Which periods should be included for working capital trend analysis? Options: Most recent fiscal year, LTM, Monthly 12 months, Quarterly 4 quarters, Custom
• Is the target seasonal or cyclical such that peak/trough adjustments are needed? Options: Yes, No, Unknown
• Will we have access to sub‑ledger detail (AR, AP, inventory) and month‑end reconciliations? Options: Full access, Partial access, Management summary only, No access yet
• Do you want working capital normalized to a target run‑rate or to an average historical level? Options: Target run‑rate, Historical average, Both (show both scenarios)
• Are there known one‑off cash timing events (e.g., customer prepayments, vendor deferrals) that should be isolated? Options: Yes, No, Unknown

Perform Revenue Cutoff and Recognition Testing

• Is revenue recognition complex (multiple element arrangements, long‑term contracts, percentage‑of‑completion) or straightforward product sales? Options: Complex (contracts/subscriptions), Mix of complex and simple, Simple product sales
• Do you want transaction‑level cutoff testing around period end(s)? Options: Yes — sample transactions, Yes — full population, No — high level only
• Which documentation will be available for testing (contracts, customer orders, shipping docs, invoices, credit memos)? Options: All items listed, Partial (specify in comments), Invoices only, Unknown
• Do you require recognition policy comparison vs. GAAP/IFRS and adjustments quantified? Options: Yes, No, Only if exceptions found
• Are there specific revenue streams or geographies you want prioritized for cutoff testing?
• Should we test for channel/consignment sales, bill‑and‑hold, or significant post‑period returns/reserves? Options: Yes, No, Only if suspected

Analyze Customer Concentration and Churn Risk

• Do you want a concentration analysis by customer and by product/service? Options: By customer only, By product/service only, Both, No
• What concentration thresholds should trigger escalation (e.g., >10% revenue from single customer)? Options: >5%, >10%, >20%, Custom (please specify)
• Should we perform churn and retention trend analysis over multiple periods? Options: Yes — 3 years, Yes — 12 months, No — snapshot only
• Will customer contract terms and renewal schedules be available for review? Options: Yes — full contracts, Partial (summaries), No
• Do you want assessment of customer credit risk and payment behavior integrated into concentration analysis? Options: Yes, No
• Are there known top‑customer risks (single buyer dependency, termination exposure, pricing concessions) we should prioritize?

Reconcile General Ledger to Financial Statements

• Do you require GL‑to‑FS reconciliations for all periods in scope or just the most recent period? Options: All periods, Most recent period only, Custom selection
• Will we have direct access to the general ledger export and chart of accounts? Options: Yes — full export, Yes — limited extracts, No — access via management only
• Are there intercompany or consolidation adjustments that need separate review? Options: Yes, No, Unknown
• Do you want identified reconciling items quantified and tracked to resolution in a schedule? Options: Yes, No
• Is the target using a single ledger system or multiple ERPs requiring mapping? Options: Single ledger, Multiple ERPs — mapping required, Unknown
• Are there known restatements or prior period adjustments we should review during reconciliation? Options: Yes, No, Unknown

Analyze Accounts Receivable Aging and Bad Debt Reserve

• Do you want a detailed AR aging analysis and testing of collections after period end? Options: Yes — detailed, High‑level only, No
• Should we test the adequacy of the bad debt reserve and methodology? Options: Yes — reestimate reserve, Yes — review policy only, No
• Will AR subledger, customer payment history, and post‑close cash collections be available? Options: Yes — full access, Partial access, No
• Are there significant disputed receivables, credit holds, or large aged balances to prioritize? Options: Yes, No, Unknown
• Do you want AR issues tied to potential purchase price adjustments or escrow triggers? Options: Yes, No, Discuss later
• Do you prefer AR testing by sample or statistical sampling? Options: Judgmental sample, Statistical sample, Full population review

Inventory Valuation and Obsolescence Testing

• Is inventory material to the balance sheet and earnings? Options: Yes — material, Moderate, No — immaterial
• Which inventory valuation methods are used (FIFO, LIFO, weighted average, standard cost)? Options: FIFO, LIFO, Weighted average, Standard cost, Other
• Do you want physical inventory observation, cycle count testing, or desk review of valuation and obsolescence? Options: Physical observation, Cycle count testing, Desk review only
• Should obsolescence reserves be re‑estimated and quantified? Options: Yes — reestimate, Review policy only, No
• Will detailed inventory subledger and SKU‑level reports be provided? Options: Yes — SKU detail, Summary level only, Unknown
• Are there slow‑moving product lines, warranty reserves, or consignment arrangements to evaluate? Options: Yes, No, Unknown

Extract Debt‑like Items and Cash Flow Adjustments

• Do you want identification and quantification of debt‑like liabilities (leases, seller notes, pensions, capitalized maintenance)? Options: Yes, No, Partial
• Should we convert operating leases to finance‑equivalent debt for leverage calculations? Options: Yes, No, Only if material
• Do you require pro forma cash flow adjustments (working capital timing, one‑off capex) for valuation modeling? Options: Yes, No
• Will debt schedules, lease contracts, and off‑balance sheet arrangements be made available? Options: Yes — full, Partial, No/unknown
• Are there known contingent liabilities or guarantees that may be considered debt‑like? Options: Yes, No, Unknown
• Do you want suggested adjustments to free cash flow and enterprise value based on extracted items? Options: Yes, No

Quantify Post‑close Integration Costs and Synergies

• Do you want a quantified estimate of one‑time integration costs and achievable synergies? Options: Integration costs only, Synergies only, Both
• Which synergy types should be targeted (cost savings, revenue synergies, SG&A rationalization)? Options: Cost savings, Revenue synergies, SG&A rationalization, Other
• What time horizon should synergy realization be modeled over? Options: 12 months, 24 months, 36 months, Custom
• Will management provide integration playbooks, org charts, and baseline costs? Options: Yes, Partial, No
• Do you expect integration costs to be capitalized or expensed for negotiation effects? Options: Capitalized, Expensed, Depends on type
• Are there critical escalation points if integration assumptions materially change valuation? Options: Yes — define escalation, No

• Statement of Work (SOW)
• Master Services Agreement (MSA)
• Fee & Payment Schedule
• Service Level Agreement (SLA) - Data & Interim Findings
• Data Room Access Agreement
• Interim Deliverables & Acceptance Criteria
• Change Order & Scope Amendment
• Confidentiality & Data Processing Agreement (DPA)
• Liability, Indemnification & Insurance
• Conflict of Interest & Independence Statement
• Subcontractor & Third-Party Vendor Clause
• Termination & Exit Terms
• Escalation & Dispute Resolution

• Acceptance Confirmation Meeting
• Final Deliverable Handover & Archive
• Post-Close Support Channel Setup & SLA Agreement
• Integration & Remediation Handover
• Lessons Learned & Playbook Update

• Schedule recurring integration status check-ins (weekly for 30 days, then bi-weekly) and invite advisory leads.
• Ensure both buyer and seller teams understand the triage process and escalation triggers to avoid stale disputes.
• Validate the workflow by running a sample ticket to confirm expectations and handoffs.
• Provision the agreed channel, invite core participants, and post the channel charter with SLAs and owners.
• Publish an escalation contact list (names, roles, phone/email) and embed into the channel pinned resources.
• Create a template for submitting post-close issues that captures claim type, supporting evidence, desired outcome, and priority.
• Top 5 Risk & Opportunity Summary
• Ensure integration teams have a prioritized, time-bound plan that maps diligence findings to operational actions.
• Assign accountable owners and KPIs to track remediation effectiveness and build visibility for the PE sponsor/IC.
• Agree on immediate next steps and the cadence for integration progress updates to advisors and the IC.
• Deliver a prioritized remediation roadmap with owners, milestones, and KPI definitions to the integration team.
• Opening & Objective
• Provide templates for KPI reporting and a tracker that maps each remediation item back to the original diligence finding.
• Timeline Retrospective
• Capture actionable lessons and concrete playbook changes that reduce future deal risk and shorten cycle times.
• Assign clear owners and deadlines for implementing playbook updates and process improvements.
• Establish measurable KPIs to track whether changes lead to faster scoping, fewer data hold-ups, and better acceptance outcomes.
• Publish a Lessons Learned report summarizing root causes, recommended playbook changes, and assigned owners.
• Update standard templates (acceptance checklist, interview requests, evidence matrix) and circulate to deal teams.
• Pilot the updated playbook on the next live deal and measure improvements against baseline KPIs.
• Obtain explicit, documented acceptance that all acceptance criteria are met or have an agreed remediation path.
• Clarify any remaining blockers and confirm whether those are deal-breakers or post-close items.
• Assign owners and deadlines to actions needed before close and capture signatures/approvals in the project record.
• Produce a one-page Acceptance Statement signed by buyer, seller (if applicable), and lead advisor confirming criteria status.
• Log any agreed post-close remediation items with owners, SLAs, and criteria that will remove escrow or adjustment triggers.
• Update the deal checklist to reflect sign-off and circulate to investment committee and transaction counsel.
• Inventory of Final Artifacts
• Ensure all stakeholders have secure access to the final deliverables and source evidence required to defend findings post-close.
• Create an auditable handover trail linking conclusions to workpapers to reduce future dispute friction.
• Confirm retention and archival responsibilities and remediation steps for any restricted materials.
• Upload final deliverables and workpapers to the agreed repository and assign documented access roles.
• Produce a short 'how-to' index (2-3 pages) mapping major report adjustments to supporting files for rapid review by counsel or IC.
• Record and close any data redaction requests and document the rationale in the archive.
• Purpose & Scope of Channel
• Create a live, agreed channel with named owners and clear SLAs to manage post-close issues without reopening the diligence period.
• Recommended Remediation Actions
• Channel Platform & Access
• Access & Archive Details
• Acceptance Criteria Walkthrough
• What Went Well / What Didn't
• Outstanding Issues & Resolutions
• Root Cause Analysis of Key Failures
• SLA & Response Tiers
• KPI & Monitoring Plan
• Forensic Traceability
• Handover Sign-offs & Documentation
• Playbook & Template Revisions
• Quick Wins & Timeline
• Escalation Matrix & Reporting
• Formal Sign-off
• Ownership & Implementation Plan
• Next Steps & Timing
• Operational Workflow Demo
• Owner Alignment & Handover Acceptance